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Objectives: The mechanism of the putative beneficial effect of myocardial transplantation of bone marrow cells
remains unclear. We studied the protective properties of bone marrow cells on the human myocardium and in-
vestigated the underlying mechanism.
Methods: Bone marrow cells and the right atrial appendage were obtained from patients undergoing elective
cardiac surgery. Myocardial slices were subjected to 90 minutes of simulated ischemia/120 minutes of reox-
ygenation at 37C following various protocols. Tissue injury was assessed by creatine kinase released into
the media during the reoxygenation period, and myocardial necrosis and apoptosis were determined by
propidium iodide and terminal deoxynucleotidyl transferase–mediated dUTP nick end labeling (percent of
aerobic control).
Results: Autologous unfractionated bone marrow cells significantly reduced myocardial injury. Maximal protec-
tion was obtained with 53 106 autologous cells (1.53 105 cells/mg wet myocardium) that caused a reduction
in creatine kinase release and cell death by necrosis and apoptosis of 70% to 80%. Allogenic bone marrow cells
were as protective as the autologous cells and their effect was unaffected by prior frozen storage or culturing.
Similar myocardial protection was also attained when bone marrow cells were present only before or during is-
chemia, or during reoxygenation, a benefit that was comparable with that of ischemic preconditioning. Condi-
tioned media by the bone marrow cells was sufficient to induce protection, which was abolished by the
selective insulin-like growth factor-1 receptor blocker PQ401.
Conclusions: Bone marrow cells possess potent myocardial protective properties that are triggered by a secreted
factor or factors and mediated by insulin-like growth factor-1 receptor. These results have important clinical impli-
cations for the therapeutic use of bone marrow cells in ischemic heart disease and for the design of future clinical
studies. (J Thorac Cardiovasc Surg 2009;138:1400-8)
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Experimental data have demonstrated that cell therapy has the
potential to repair the damaged myocardium. This expecta-
tion and the clinical need for an effective treatment to reduce
the injury sustained during an acute myocardial infarction and
to repair the failing heart have accelerated the performance of
clinical trials mainly using bone marrow cells (BMCs), even
before the underlying mechanisms have been elucidated.
However, the outcomes of the randomized clinical trials
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among the cell composition and manipulation of BMCs may
be responsible for the observed differences among some of
these studies.4 All this has prompted investigators to go
back to the laboratory to clarify what BMCs can do, to identify
the cellular/molecular mechanisms involved, and also to de-
fine the best modalities of application.
Beside the regenerative capacity, BMCs can act through
a paracrine mechanism to increase angiogenesis and to re-
duce cell death.5,6 Recently, our laboratory has demon-
strated that BMCs reduce cell necrosis and apoptosis of
the human myocardium7 in an acute in vitro nonperfused
model, suggesting that the effect could be due, at least in
part, to a direct effect of the BMCs on the myocardium
and may not necessarily be a consequence of improved vas-
cularity and blood supply. One of the mechanisms that may
be responsible for the BMC-induced benefit on the ischemic
myocardium is through a paracrine action by reducing cell
death and/or by preservation and activation of resident
stem cells. Hence, the aims of the present studies were (1)
to investigate the mechanism of BMC-induced myocardial
protection and (2) to identify whether the manipulation of
BMCs, the time of their administration, and the cell type in-
fluence this beneficial effect.urgery c December 2009
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BMC ¼ bone marrow cell
CK ¼ creatine kinase
DAPI ¼ 406-diamidino-2-phenylindole
ELISA ¼ enzyme-linked immunosorbent assay
IGF ¼ insulin-like growth factor
IGF-1R ¼ insulin-like growth factor-1 receptor
IP ¼ ischemic preconditioning
I/R ¼ ischemia/reoxygenation
KHH ¼ Krebs/Henseleit/Hepes
METHODS
Study Patients
The right atrial appendage from patients aged 44 to 82 years and under-
going elective heart surgery for coronary bypass or aortic valve replacement
was obtained before the initiation of cardiopulmonary bypass. These pa-
tients were routinely receiving cardioactive drugs according to standard pre-
scriptions (ß-blockers, angiotensin-converting enzyme inhibitors, statins,
and aspirin or clopidogrel). Ethical considerations prevented us from dis-
continuing the drugs more than 24 hours before the operation; however, pre-
viously we have observed (unpublished data) that these medications have no
effect on the tolerance of the atrial myocardium to ischemia and its response
to ischemic preconditioning. Patients with atrial fibrillation, cancer, diabe-
tes, poor left ventricular function (ejection fraction< 30%) or with addi-
tional surgical procedures or those being treated until the initiation of
surgery with opioids, catecholamines, or the adenosine triphosphate potas-
sium–channel opener nicorandil, were excluded from the study. The study
was conducted according to Declaration of Helsinki principles and approval
was obtained from the local ethics committee. All participants provided
written consent.
Experimental Preparation
The experimental preparation has been previously described and fully
characterized.8 After resection, atrial samples were immediately immersed
in cold (4C) Krebs/Henseleit/Hepes (KHH) medium containing (in micro-
moles per liter) NaCl 118, KCl 4.8, NaHCO3 27.2, KH2PO4 1, MgCl2 1,
CaCl2 1.25, glucose 10, and Hepes 20, with a pH of 7.4. Tissues were im-
mediately sectioned with a skin-graft blade (Swann-Morton Ltd, Sheffield,
United Kingdom) to slices of 30- to 50-mg weight and 300- to 500-mm
thickness. After this, myocardial sections were equilibrated under normo-
thermic aerobic conditions (95% O2/5% CO2) for 50 to 60 minutes and
then subjected to 90 minutes of simulated ischemia at 37C, obtained by
continuously bubbling the media with 95% N2/5% CO2 in the absence
of glucose and at pH of 6.8, followed by 120 minutes of reoxygenation.
For the induction of ischemic preconditioning (IP), myocardial slices
were subjected to 5 minutes of ischemia followed by 5 minutes of reoxyge-
nation before induction of the 90-minute ischemic period.9
Aspiration and Preparation of BMCs
Under general anesthesia and before initiation of cardiac surgery, bone
marrow (50–80 mL) was aspirated from the patient’s iliac crest. Fresh
BMCs were separated by density centrifugation with Lymphoprep solution
(AXIS-SHIELD PoC AS, Oslo, Norway).
Some cells were cultured in GlutaMAX media (Gibco; Invitrogen Cor-
poration, Carlsbad, Calif) containing 10% fetal bovine serum (HyClone,
Logan, Utah) plus penicillin and streptomycin at concentrations of 100
IU/mL and 100 mg/mL, respectively (Lonza, Basel, Switzerland) for 7The Journal of Thoracic and Cadays in 5% CO2/95% O2 at 37
C. After this, all the cells in the culture
were collected and resuspended in KHH solution for their experimental use.
For freezing, the fresh cells were resuspended in fetal bovine serum con-
taining 10% dimethyl sulfoxide (Sigma-Aldrich, Dorset, United Kingdom)
and stored at80C in cryovials overnight, then transferred to liquid nitro-
gen, where they were kept until used. For experimental use, cells were
thawed, washed, and resuspended in KHH solution.
BMC viability was assessed by the absorption of Trypan blue (Sigma-
Aldrich) in which cells that did not exclude the dye and stained with dark
blue were considered as dead.
Assessment of Tissue Injury
Tissue injury was assessed by measurement of creatine kinase (CK) re-
lease into the media during the reoxygenation period. CK was measured by
the enzyme-linked immunosorbent assay (ELISA) method with a plate
reader (Benchmark, Bio-Rad Laboratories, Hercules, Calif) using a commer-
cial CK assay kit (30-3060/R2; Abbott Laboratories, Kent, United King-
dom) and expressed as international units per milligram of wet tissue
Assessment of Cell Death
At the end of the experimental protocol, to assess necrosis, we incubated
tissues for 15 minutes at room temperature with 20 mg/mL propidium iodide
(Sigma-Aldrich). Muscles were fixed with 4% paraformaldehyde and
frozen sections were then cut at 7-mm thickness.
To assess apoptosis, the slides were stained with fluorescein isothiocya-
nate employing terminal deoxynucleotidyl transferase–mediated dUTP nick
end labeling technique (Roche Diagnostics, Penzberg, Germany). A nega-
tive control, obtained by not adding the enzyme solution, was performed ev-
ery time.
To distinguish the total number of nuclei, myocardial sections were
counterstained with 1 mg/mL 406-diamidino-2-phenylindole (DAPI, Molec-
ular Probes, Eugene, Ore) for 1 minute and mounted them with anti-fade so-
lution (Prolong Antifade kit, Molecular Probes, Eugene, Ore).
An Axiovert 200 M fluorescent microscope (Carl Zeiss, Go¨ttingen,
Germany) at 403 magnification was used to assess necrosis and apoptosis.
At least 10 fields per section were examined for each experiment. Propidium
iodide and fluorescein isothiocyanate–labeled nuclei were detected by the
Cy3 and enhanced green fluorescence protein channels, respectively,
whereas DAPI labeling was detected by the DAPI channel. Only the necrotic
or apoptotic signals coinciding with DAPI were considered true events. The
National Institutes of Health Image software (Scion Corp, Frederick, Md)
was used to determine the total events for each field. To avoid the inclusion
of artifacts, we counted only signals with areas greater than 16 mm2.
Assessment of Insulin-Like Growth Factor (IGF)-1
and IGF-2
ELISA method was used to analyze the concentration of IGF-1 and IGF-
2 in the conditioned media by employing human IGF-1 detection kit (R&D,
Minneapolis, Minn) and human IGF-2 detection kit (Biosupply, Norwich,
Norfolk, United Kingdom) as described by the manufacturers. The minimal
detection limit of the procedure was 62.5 ng/mL for IGF-1 and 40 ng/mL for
IGF-2.
Study Protocols
In each study, myocardial slices (n ¼ 6/group in each study, unless indi-
cated) were randomly allocated to different groups. The right atrial append-
age from each donor supplied sufficient muscle slices for all the groups in
every study, so that the number of myocardial slices used in each group rep-
resents the number of donor patients. Some muscles were aerobically incu-
bated for the whole experimental time serving, as time-matched aerobic
controls, and others subjected to 90 minutes of simulated ischemia plus
120 minutes of reoxygenation alone served as ischemic controls. Freshrdiovascular Surgery c Volume 138, Number 6 1401
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and frozen BMCs were also used in study 3. The studies were sequentially
carried out as described below:
Study 1: To study the most effective BMC dose to induce
myocardial protection. To find out the number of BMCs required
to obtain maximal protection, we coincubated different doses of cells
(0.5, 1, 5 and 103 106 cells/preparation) with the myocardial slices during
ischemia/reoxygenation (I/R).
Study 2: To determine the potency of BMCs and
whether the time of administration influences myocar-
dial protection. Fresh autologous BMCs (5 3 106cells/preparation)
were coincubated with atrial myocardial slices during ischemia, during re-
oxygenation alone, or during both times (throughout) and compared with
the effect of IP.
Study 3: To investigate whether the source and the ma-
nipulation (culture, freezing) of BMCs affect their pro-
tective effect. Because the study on the manipulation of BMCs
would require the use of allogenic cells, it was necessary to identify first
whether the source of cells has an influence on the degree of protection.
To this end, we incubated myocardial slices during I/R with fresh autolo-
gous and fresh allogenic BMCs (5 3 106 cells/preparation). Additionally,
we incubated myocardial slices during I/R with fresh autologous BMCs
and with allogenic cells cultured for 7 days or frozen for 1 to 9 weeks.
Study 4: To investigate whether BMCs can precondition
the myocardium. BMCs were coincubated with the myocardial slices
for different time periods (10, 20, and 30 minutes) before I/R, and their anti-
ischemic effect was compared with the one obtained with IP. To reduce the
possibility that the concentrations of BMCs could play a role, particularly
with the shorter periods of co-incubation, we selected a dose of 10 3 106
cells/preparation for this study.
Study 5: To investigate whether the myocardial protec-
tion induced by BMCs is mediated by secreted factor(s).
BMCs (103 106cells/preparation) were incubated in 10 mL KHH solution
under aerobic condition for 30 minutes. The conditioned media (superna-
tant) was then obtained and coincubated with myocardial slices for another
30 min before I/R. For comparison, the effect of BMCs (10 3 106 cells/
preparation), also coincubated with the muscles for the same time period,
and that of IP were studied.
Study 6: To elucidate whether IGF-1 receptors (IGF-1R)
are mediating the protection induced by BMCs. IGF-1 is
produced by BMCs and both IGFs (IGF-1 and IGF-2), whose biological ac-
tivity is mediated mainly through IGF-1R, have been shown to induce car-
dioprotection.10-14 To investigate whether the obtained protective effect of
BMCs is mediated by IGF-1R, we incubated atrial myocardial slices for 30
minutes with conditioned media, obtained from the culture of 10 3 106
BMCs for 30 minutes, before I/R. Experiments were performed in the pres-
ence of various concentrations (0, 1.5, 15, and 150 mmol/L) of the specific
IGF-1R blocker PQ401 (Sigma-Aldrich) that directly inhibits autophos-
phorylation of the kinase domain of the receptor.15
In additional studies, the concentration of IGFs secreted into the media
by 103 106 BMCs was determined after 10, 20, and 30 minutes of incuba-
tion (n¼ 6/group). To examine whether the observed benefit from BMCs is
mediated by the IGFs present in the media, we incubated atrial myocardial
slices with IGF-1 at the concentration of 62.5 ng/mL and IGF-2 at the con-
centration of 40 ng/mL (both from Sigma-Aldrich) alone and in combina-
tion for 30 minutes before I/R. These concentrations represented the
minimal detected levels in the BMCs-conditioned media by ELISA.
Study 7: To investigate whether CD133þcells are respon-
sible for the myocardial protection induced by BMCs.
To identify whether CD133þ cells, a subset of BMCs that have been used
in clinical trials for cardiac repair,16-18 are responsible for myocardial pro-1402 The Journal of Thoracic and Cardiovascular Sutection induced by BMCs, we incubated atrial myocardial slices (n ¼
5/group) with autologous CD133þ and CD133 cells for 30 minutes before
I/R. CD133þ cells were isolated using antibody-magnetic beads (Miltenyi
Biotec, Bergisch Gladbach, Germany). After that, the percentage of
CD133þ in the selected cell population was determined. The CD133þ and
CD133 cells used in each preparation were those obtained from 10 3 106
BMCs. In addition, myocardial slices were also subjected to an identical
protocol using unfractionated BMCs (10 3 106 cells).
Statistical Analyses
Data are expressed as mean SEM. Values were obtained after subtract-
ing the corresponding time-matched aerobic control values. One-way anal-
ysis of variance followed by the Bonferroni test were used to compare the
significance between groups. Analyses were performed using the SPSS pro-
gram (SPSS, Inc, Chicago, Ill).
RESULTS
Cell viability after isolation of each BMCs preparation used
and prior experiment was greater than 95% in all instances.
Dose-Response Study (Study 1)
Figure 1, A to C, shows that CK release and the percent of
cell necrosis and apoptosis seen in the atrial myocardial sli-
ces subjected to I/R alone were not significantly affected by
doses of 13 106 BMCs or less. However, significant reduc-
tion in all indexes of injury was observed at a dose of 53 106
cells, equivalent to 0.142  0.0063 106 cells/mg wet myo-
cardium, with no additional improvement at the higher dose.
The Potency of BMCs and the Role of the Time of
Administration (Study 2)
Figure 2,A toC, shows that the incubation of atrial myocar-
dial slices with BMCs during the ischemic or reoxygenation
period alone was equally effective in reducing myocardial
CK release and cell death seen in I/R alone and that the pro-
tection observed in the 2 groups was similar to that of
BMCs when present during I/R and also that of IP.
The Effect of the Source and the Manipulation of
BMCs (Study 3)
The results show that allogenic BMCs reduce the CK
release and cell death seen in the I/R alone group to a degree
identical to that obtained with autologous BMCs (Figure E1).
Figure 3 shows that both methods, the culture (Figure 3, A to
C) and the freezing (Figure 3,D toF) of allogenic BMCs, sig-
nificantly reduce CK release and cell death when compared
with I/R alone, an effect that again was comparable with
the one observed with autologous fresh BMCs.
Preconditioning With BMCs (Study 4)
As seen in Figure 4, A to C, the incubation of atrial myo-
cardial slices with BMCs for 10, 20, and 30 minutes before
I/R resulted in progressive protection as compared with I/R
alone, with maximal protection in the 30-minute group,
values that were almost identical to those obtained with IP.rgery c December 2009
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Figure 5, A to C, shows that the conditioned media signif-
icantly reduced CK release and cell death, as compared with
I/R alone, when coincubated with the atrial myocardial sli-
ces for 30 minutes before I/R. The results were almost iden-
tical with those obtained by preconditioning with BMCs
(30 minutes) or by IP, suggesting that the observed protec-
tive effect is mediated by a factor or factors produced by
BMCs and contained in the conditioned media.
Role of IGF-1R in BMC-Induced Myocardial
Protection (Study 6)
Figure 6, A to C, shows that the specific IGF-1R blocker
PQ401 at the highest concentration used (150 mmol/L) did
not affect CK release and cell death caused by I/R. It also
demonstrates that the favorable effect of the conditioned me-
dia was abolished by PQ401 at concentrations of 15 mmol/L
or more, suggesting that IGF-1R is required for the protec-
tion induced by BMCs.
IGF-1 and IGF-2 could not be detected by the commercial
ELISA kits in the conditioned media at the end of 30 minutes
of incubation with BMCs. Because of that, the minimum de-
tectable concentrations for the assays of the 2 factors (62.5
ng/mL for IGF-1 and 40 ng/mL for IGF-2) were used instead
of the BMCs and the conditioned media. The results demon-
strated that IGF-1 and IGF-2 in combination at a concentra-
tion above the level present in the conditioned media by
themselves did not significantly affect the CK release and
cell death caused by I/R (data not shown), thus suggesting
that either factor(s) other than IGF-1 and IGF-2 are acting
through the IGF-1R to produce the protective effect or that
FIGURE 2. The potency of myocardial protection by BMCs as compared
to ischemic preconditioning (IP) and the role of the time of administration of
BMCs on CK release (A), cell necrosis (B), and apoptosis (C). BMC, Bone
marrow cell; CK, creatine kinase; I/R, ischemia/reoxygenation; I, BMCs ad-
ministered during ischemia only; R, BMCs administered during reoxygena-
tion only, IþR, BMCs administered during I/R. *P<.05 versus I/R alone.
FIGURE 1. Dose-response effect of BMCs on CK release (A) and cell
necrosis (B) and apoptosis (C). *P< .05 versus I/R alone. BMC, Bone
marrow cell; CK, creatine kinase; I/R, ischemia/reoxygenation.The Journal of Thoracic and Cardiovascular Surgery c Volume 138, Number 6 1403
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achieve the benefit induced by BMCs and requires the con-
comitant effect of additional factor(s).
Role of CD133þCells (Study 7)
The results demonstrate that although the reduction in CK
release and cell death can be replicated by the incubation of
the myocardial slices with BMCs for 30 minutes before I/R,
the CD133þ (0.3  0.04% BMCs) and CD133 population
failed to significantly modify the mean values for the 3 in-
dexes of injury seen in the I/R alone group (data not shown).
DISCUSSION
We have demonstrated that the protection of the human
myocardium induced by BMCs is mediated through the
IGF-1R. Because the protective effect of BMCs cannot be
replicated by the combine use of IGF-1 and IGF-2, it is clear
that although these factors could be necessary they are not
sufficient to induce protection and that other as yet unknown
BMCs-secreted factor(s) are required. In addition, we have
elucidated the optimal conditions necessary to obtain maxi-
mal benefit, thus opening the door for a more effective clin-
ical application of BMCs.
BMCs and Myocardial Protection
Our results provide clear evidence on the capacity of
BMCs, whose potency is similar to that of IP, to induce pro-
tection of the human myocardium by significantly decreas-
ing the death of cells at risk, a finding that is in agreement
with our previous results.7 Other studies have also suggested
that ischemic changes in experimental animal models can be
prevented or decreased by BMCs via a paracrine effect.5
Therefore, it is possible that the modest improvement in car-
diac function seen in some clinical trials using BMCs is due,
at least in part, to an early effect that reduces the loss of cells
destined to die in the area at risk. Of course, such a mecha-
nism would not exclude the possibility that BMCs may ame-
liorate cardiac function by late tissue regeneration either via
FIGURE 3. The effect of culture (A, B, and C) and freezing (D, E, and F) on the capacity of BMCs to reduce CK release and cell necrosis and apoptosis.
BMC, Bone marrow cell; CK, creatine kinase; I/R, ischemia/reoxygenation. *P< .05 versus I/R alone.1404 The Journal of Thoracic and Cardiovascular Surgery c December 2009
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stimulation of resident stem cells, although these are two
topics that remain the source of intense debate.
Here we have also shown that the myocardial protection of
BMCs is dose-dependent but plateaus at about 1.5 3 105
BMCs/mg wet myocardium. This means that 71 3 109 (or
1011) BMCs could be required to obtain optimal protection
of a heart weighting 500 g. This is an important finding that
may explain the variable results reported by recent clinical
trials.2,3 It is worth noting that the doses of cells used in these
trials were well below the optimal dose seen in our study, and
it is possible that the reported benefit was only partial. The
argument that the myocardial protection of BMCs is dose-
dependent is reinforced by the finding that reduced mortality
was seen in patients with established postinfarction heart fail-
ure receiving a high number of BMCs.19 Moreover, meta-
analyses of clinical trials on intracoronary BMC therapy after
acute myocardial infarction have also suggested the exis-
tence of a dose-response association between injected cell
number and left ventricular ejection fraction change.2,3
Therefore, the design of future clinical studies must take
into consideration the importance of selecting an appropriate
dose of BMCs, although it may be possible to speculate that
stimulation of BMCs, such as hypoxia, will produce more
factors that could compensate for a lower number of cells ad-
ministered.12 Furthermore, the demonstration that less than
5% of the BMCs administered via the coronary arteries re-
main in the myocardium is an additional concern that would
account for the critical issue of cell dosage.20
Another important finding of these studies is that the pro-
tection by BMCs can be obtained when cells are applied
FIGURE 4. The effect of preconditioning with BMCs, induced by coincu-
bation of cells with muscles for various time periods before ischemia, on CK
release (A), cell necrosis (B), and apoptosis (C). Some muscles were also
subjected to ischemic preconditioning (IP). BMC, Bone marrow cell; CK,
creatine kinase; I/R, ischemia/reoxygenation. *P< .05 versus I/R alone.
FIGURE 5. The effect of preconditioning with conditioned media, as com-
pared with BMCs and ischemic preconditioning (IP), on CK release (A),
cell necrosis (B), and apoptosis (C). BMC, Bone marrow cell; CK, creatine
kinase; I/R, ischemia/reoxygenation. *P< .05 versus I/R alone.The Journal of Thoracic and Cardiovascular Surgery c Volume 138, Number 6 1405
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the degree of protection is similar in all instances without
further improvement when they are administered at more
than one time point. However, it should be noted that in
our studies BMCs were administered for the first 2 hours
of reoxygenation and that it is not known whether they
may be as effective when given at later stages of reperfusion.
Indeed, the time of BMC administration after a myocardial
infarction has been argued as a key factor to improve cardiac
function,21 and a clear improvement was claimed in a prelim-
inary report when the BMCs were administered in the first
few hours after the myocardial infarction.22 Therefore, fur-
ther studies will be required to characterize the time course
of the benefit.
FIGURE 6. The effect of the specific IGF-1R blocker PQ401 at different
concentrations in the conditioned media, when coincubated with the mus-
cles for 30 minutes before ischemia, on CK release (A), cell necrosis (B),
and apoptosis (C). BMC, Bone marrow cell; CK, creatine kinase; I/R, ische-
mia/reoxygenation; IGF-R1, insulin-like growth factor-1 receptor. *P<.05
versus I/R alone.1406 The Journal of Thoracic and Cardiovascular SAllogenic BMCs and Effect of Cell Manipulation
Transplantation of allogenic BMCs has been shown to be
feasible and effective clinically23; however, the present stud-
ies have demonstrated for the first time that allogenic BMCs
protect the myocardium against ischemic injury to a degree
similar to that of autologous BMCs. They also suggest that
allogenic BMCs, being readily available, could be success-
fully applied in clinical conditions where autologous cells
cannot be timely prepared or are defective. It should be con-
ceded that immune reaction remains a considerable problem
after allogenic cell transplantation,23 but allogenic mesen-
chymal stem cells, a subset of BMCs, have been reported
to engraft without rejection and contribute to heal necrotic
tissue.24 The results obtained with conditioned media sug-
gest that it might be possible to devise therapeutic ap-
proaches that have the advantages of the allogenic cells,
such as ready availability at all times, without the potential
immunologic drawbacks.
Although manipulation of BMCs by freezing and cultur-
ing of cells does not abolish myocardial protection, previ-
ously it has been suggested that subtle differences in cell
processing and storage may affect the number and function-
ality of infused progenitor cells that, in turn, could explain
the discordance between clinical trials.4 We cannot fully ex-
plain the discrepancy between these claims and the results
reported here. However, whereas the protective effect was
investigated in our studies, the capacity to engraft was as-
sessed in the other study.4
Mechanism of Action
We have shown that the protection of the human myocar-
dium by BMCs is mediated by a secreted factor(s) that re-
quires the incubation of cells for at least 30 minutes to
sufficiently accumulate in the media to achieve maximal
therapeutic efficacy. These results in man are supported by
an animal study showing that the use of conditioned media
from BMCs significantly increases microvessel density, de-
creases fibrosis, and prevents apoptosis in the infarcted myo-
cardium, thus leading to improvement in cardiac function.11
However, in this experimental study, the conditioned media
was obtained after culturing BMCs and then administered
directly into the myocardium immediately after coronary li-
gation and subsequently intraperitoneally at several time
points after infarction.11
The myocardial protection obtained with BMCs or the
BMC-conditioned media was as potent as that of IP. A pre-
vious study from our laboratory7 demonstrated that the
BMC-induced myocardial protection can be abolished by
blocking the activation of kinases such as PKC and
p38MAPK, both of which have been shown to be integral
parts of the signaling transduction mechanism of IP.25 These
kinases are also downstream effectors of the IGF-1R.26
Therefore, it is likely that BMCs and IP are sharing some
of the mechanism required to elicit their protective action.urgery c December 2009
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essary mediator of the myocardial protection induced by
BMC-conditioned media since the benefit was completely
abolished by the IGF-1R–specific antagonist PQ401 in
a dose-dependent manner. This finding would suggest
that a factor responsible for the beneficial action of the
BMC-conditioned media is IGF, a thesis that would be
supported by previous experimental studies on the protec-
tive properties of this growth factor.10,27 However, IGF-1
and IGF-2 were below the level of detection of the com-
mercial ELISA kit in the BMC-conditioned media, and
when both IGFs were used at higher concentrations to
those present in the media they were not sufficient to re-
duce ischemic injury. These results suggest that factor(s)
other than IGF-1 and IGF-2 acting through IGF-1R are
necessary to induce protection. Given the complex biolog-
ical actions triggered by the BMCs or their conditioned
medium, it seems reasonable that other factors alone or
in combination with IGF are needed to produce myocar-
dial protection. Certainly, a full elucidation of the factor(s)
responsible for cardioprotection would require further in-
vestigation.
In clinical studies, CD133þ cells have been reported to
possess regeneration potential18 and to promote cardiac re-
covery after a recent myocardial infarction.16 Because of
this, and due to its stemness potential, we investigated
whether the CD133þ cells in the preparation are responsible
for the BMC-induced myocardial protection. Unfortunately,
neither the CD133þnor the remaining BMC population was
able to reduce ischemic injury. This suggests that cell sepa-
ration by magnetic immunobeads impairs the capacity of
cells to secrete the factor(s) accountable for the reduction
in ischemic injury.
LIMITATIONS
A limitation of our studies is the use of atrial tissue, inas-
much as it may not fully represent the response of ventricular
myocardium. Nonetheless, recent studies in our laboratory
(unpublished data) have shown that the degree of injury in-
duced by I/R of the human atrial myocardium is similar to
the one observed in muscles from the left ventricle of mice
and rats, suggesting that the response of the atrial and ven-
tricular myocardium to I/R is comparable. In addition, we
(unpublished data) and other investigators28 have shown
that a comparable level of protection occurs with precondi-
tioning in atrial and ventricular myocardium. Another poten-
tial limitation may be that all the studies were performed in
an in vitro preparation that is devoid of blood components.
However, the latter shortcoming could also be advantageous
to examine the direct relationship between the intervention
and the myocardium, removing the potential confounding
effects of blood and vasculature. Despite the above consid-
erations, caution must be taken when extrapolating the pres-
ent results to clinical conditions.The Journal of Thoracic and CaWe acknowledge Ms Lakshmi Srinivasan, Ms Wendy Rathbone,
and Mrs Nicola Harris for their help, and also the Take Heart
Leicester and Glenfield Hospital Cardiac Surgery Theater for their
assistance.
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